Dr. Xinyang Yu

B.S., Jinlin Medical college, 2014                     Clinical Medicine

M.S., Harbin Medical University, 2017             Advisor: Prof. Hongyu Kuang

Ph.D., Harbin Medical University, 2021              Advisor: Prof. Hongyu Kuang

Selected Publications
  • Xinyang Yu, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.  Eur J Pharmacol 2019, 864, 172715. 

  • Xinyang Yu, et al. Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by modulating miR-342-3p targeting of CASP1 in diabetic retinopathy. Exp Eye Res 2021, 202, 108300. 

Comprehensive introduction

The main direction of her previous research was the study of the pathogenesis of diabetes and its complications, and to explore the potential molecular mechanisms of emerging drugs. The current research direction is tumor immunotherapy based on supramolecular materials. 

Copyright, Supramolecular Theranostic Lab   All Rights Reserved.sitemap

Quick links: Research | Members | Publications | News| Gallery | Join Us

Useful links: Tsinghua | Tsinghua Chem | Tsinghua Library | Web of Science | Science I Nature I Cell I ACS